Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog–Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032

PURPOSE: Two phase II studies assessed the efficacy of vismodegib, a sonic hedgehog (SHH) pathway inhibitor that binds smoothened (SMO), in pediatric and adult recurrent medulloblastoma (MB). PATIENTS AND METHODS: Adult patients enrolled onto PBTC-025B and pediatric patients enrolled onto PBTC-032 w...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Robinson, Giles W., Orr, Brent A., Wu, Gang, Gururangan, Sridharan, Lin, Tong, Qaddoumi, Ibrahim, Packer, Roger J., Goldman, Stewart, Prados, Michael D., Desjardins, Annick, Chintagumpala, Murali, Takebe, Naoko, Kaste, Sue C., Rusch, Michael, Allen, Sariah J., Onar-Thomas, Arzu, Stewart, Clinton F., Fouladi, Maryam, Boyett, James M., Gilbertson, Richard J., Curran, Tom, Ellison, David W., Gajjar, Amar
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2015
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC4534527/
https://ncbi.nlm.nih.gov/pubmed/26169613
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.60.1591
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires